Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Karl

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Health Policy (Amsterdam, Netherlands)|September 16, 2018
Physicians' comprehension of the German Patients' Rights Act: A cross-sectional studyDaniel Karl-Heinz Voigt, Philipp Lenz, Hendrik Friederichs
Cancer Research|January 28, 2010
RETRACTED: Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1Yoon-Jin Lee, Moritz Koch, Daniel Karl, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2026
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 studyArndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, et al.
Nature Communications|October 31, 2019
TAF1 plays a critical role in AML1-ETO driven leukemogenesisYe Xu, Na Man, Daniel Karl, et al.
Biomaterials|December 8, 2017
Strontium and bisphosphonate coated iron foam scaffolds for osteoporotic fracture defect healingSeemun Ray, Ulrich Thormann, Marlen Eichelroth, et al.
The Journal of Clinical Investigation|May 18, 2023
The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expressionGloria Mas, Na Man, Yuichiro Nakata, et al.
Cancer Cell|June 13, 2018
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal HematopoiesisSarah M Greenblatt, Na Man, Pierre-Jacques Hamard, et al.
Cell Reports|February 27, 2023
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemiaJohn P Brabson, Tiffany Leesang, Yoon Sing Yap, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Health Policy (Amsterdam, Netherlands)|September 16, 2018
Physicians' comprehension of the German Patients' Rights Act: A cross-sectional studyDaniel Karl-Heinz Voigt, Philipp Lenz, Hendrik Friederichs
Cancer Research|January 28, 2010
RETRACTED: Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1Yoon-Jin Lee, Moritz Koch, Daniel Karl, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2026
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 studyArndt Vogel, Najib Ben Khaled, Javier Ruiz Ramirez, et al.
Nature Communications|October 31, 2019
TAF1 plays a critical role in AML1-ETO driven leukemogenesisYe Xu, Na Man, Daniel Karl, et al.
Biomaterials|December 8, 2017
Strontium and bisphosphonate coated iron foam scaffolds for osteoporotic fracture defect healingSeemun Ray, Ulrich Thormann, Marlen Eichelroth, et al.
The Journal of Clinical Investigation|May 18, 2023
The SWI/SNF chromatin-remodeling subunit DPF2 facilitates NRF2-dependent antiinflammatory and antioxidant gene expressionGloria Mas, Na Man, Yuichiro Nakata, et al.
Cancer Cell|June 13, 2018
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal HematopoiesisSarah M Greenblatt, Na Man, Pierre-Jacques Hamard, et al.
Cell Reports|February 27, 2023
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemiaJohn P Brabson, Tiffany Leesang, Yoon Sing Yap, et al.
Pageof 1